A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer
Status:
Active, not recruiting
Trial end date:
2036-11-30
Target enrollment:
Participant gender:
Summary
Multi-center, open-label, Phase 1 study of the safety, tolerability and feasibility of dosing
patients harboring metastatic castration resistant prostate cancer (mCRPC) with genetically
modified autologous T cells (CART-PSMA-TGFβRDN cells) engineered to express a chimeric
antigen receptor (CAR) capable of recognizing the tumor antigen prostate-specific membrane
antigen (PSMA) and activating the T cell.
Phase:
Phase 1
Details
Lead Sponsor:
Tmunity Therapeutics
Treatments:
Cyclophosphamide Fludarabine Fludarabine phosphate Interleukin 1 Receptor Antagonist Protein